1. Introduction {#sec1-marinedrugs-18-00076}
===============

Since the first scalarane-type derivative, scalarin, was originally isolated from *Cocaspongia scalaris* \[[@B1-marinedrugs-18-00076]\], more than three hundred scalarane sesterterpenoids have been obtained from cyanobacteria and marine organisms \[[@B2-marinedrugs-18-00076],[@B3-marinedrugs-18-00076]\]. Compounds of this type demonstrate a wide spectrum of interesting biological properties, such as anti-inflammation \[[@B4-marinedrugs-18-00076]\], cytotoxicity \[[@B5-marinedrugs-18-00076],[@B6-marinedrugs-18-00076],[@B7-marinedrugs-18-00076]\], anti-feedant \[[@B8-marinedrugs-18-00076],[@B9-marinedrugs-18-00076],[@B10-marinedrugs-18-00076]\], anti-microbial activity \[[@B11-marinedrugs-18-00076],[@B12-marinedrugs-18-00076]\], ichthyotoxicity \[[@B13-marinedrugs-18-00076]\], anti-tubercular activity \[[@B14-marinedrugs-18-00076]\], anti-HIV \[[@B15-marinedrugs-18-00076]\], and inhibition of the nuclear hormone receptor \[[@B16-marinedrugs-18-00076]\]. In order to seek novel anti-proliferative substances from marine organisms, a chemical and bioactive investigation was carried out on the organic extracts of a marine sponge identified as *Lendenfeldia* sp. (family---Thorectidae). The ethyl acetate (EtOAc) extract of *Lendenfeldia* sp. was found to exhibit anti-proliferative activity against human cancer cell lines, including human acute lymphoblastic leukemia (MOLT-4), human chronic myelogenous leukemia (K-562), human histiocytic lymphoma (U-937), and human T-cell lymphoblastic lymphoma (SUP-T1) with IC~50~ values \< 0.625 μg/mL. The bioassay-guided isolation, combined with an NMR spectroscopic pattern-based procedure, was used to explore the anti- proliferative scalarane substances, and led to the isolation four new 24-homoscalaranes, lendenfeldaranes A--D (**1**--**4**), along with three known metabolites, 12α-acetoxy-22-hydroxy-24- methyl-24-oxoscalar-16-en-25-al (**5**) \[[@B17-marinedrugs-18-00076]\], felixin F (**6**) \[[@B18-marinedrugs-18-00076]\], and 24-methyl-12,24,25-trioxoscalar-16- en-22-oic acid (**7**) \[[@B17-marinedrugs-18-00076]\]. In the current study, the comprehensive workflow of isolation, structure elucidation and an anti-proliferative evaluation were implemented on scalaranes **1**--**7** ([Figure 1](#marinedrugs-18-00076-f001){ref-type="fig"}).

2. Results and Discussion {#sec2-marinedrugs-18-00076}
=========================

Lendenfeldarane A (**1**) was obtained as an amorphous powder and assigned the molecular formula C~28~H~42~O~6~ (eight degrees of unsaturation) from its (+)-HRESIMS at *m*/*z* 497.28736 \[M + Na\]^+^ (calcd. for C~28~H~42~O~6~ + Na, 497.28712). The ^1^H NMR data of **1** ([Table 1](#marinedrugs-18-00076-t001){ref-type="table"}), showed six singlet methyls at δ~H~ 0.75, 0.86, 0.96, 1.16, 2.14, and 2.29, one olefinic proton at δ~H~ 6.90 (1H, br s), and one oxymethine proton at δ~H~ 4.77 (1H, br s). The diastereotopic geminal protons at δ~H~ 3.85 (1H, d, *J* = 11.6 Hz) and 4.02 (1H, d, *J =* 11.6 Hz) were assumed to be an oxymethylene group. Analyses of the ^13^C and distortionless enhancement by polarization transfer (DEPT) spectra of **1** ([Table 1](#marinedrugs-18-00076-t001){ref-type="table"}) revealed the existence of 28 carbon resonances, including six methyls, eight sp^3^ methylenes (including one oxymethylene), five sp^3^ methines (including one oxymethine), four sp^3^ quaternary carbons, one sp^2^ methine, and four sp^2^ quaternary carbons (including three carbonyls). Based on the ^1^H and ^13^C NMR spectra, **1** was found to possess an acetoxy group (δ~H~ 2.14, 3H, s; δ~C~ 170.4, C; 21.5, CH~3~). An additional unsaturated functionality was indicated by ^13^C resonances at δ~C~ 139.7 (CH-16) and 137.9 (C-17), suggesting the presence of a trisubstituted olefin. Thus, four degrees of unsaturation were accounted for, and the above NMR data---as well as the unassigned degrees of unsaturation of **1**---implied a tetracyclic analogue.

The gross structure of **1** was further established from its 2D NMR spectra. From the coupling information in the COSY spectrum of **1** ([Figure 2](#marinedrugs-18-00076-f002){ref-type="fig"}), it was possible to establish four partial structure units between H~2~-1/H~2~-2/H~2~-3, H-5/H~2~-6/H~2~-7, H-9/H~2~-11/H-12, and H-14/H~2~-15/H~2~-16. The heteronuclear multiple bond correlation (HMBC) spectrum connected these substructures by the connectivity between H-5/C-10; H-16/C-17; H~3~-20/C-3, C-4, C-5, C-19; H~3~-21/C-7, C-8, C-9, C-14; H~2~-22/C-1, C-9, C-10; H~3~-23/C-12, C-13, C-14, C-18; and H~3~-26/C-17, C-24, indicating a scalarane-type sesterterpenoid structure ([Figure 2](#marinedrugs-18-00076-f002){ref-type="fig"}). Furthermore, the acetoxy and carboxylic acid groups positioned at C-12 and C-18 were determined by the HMBC, from H-12 to the acetate carbonyl at δ~C~ 170.4 and from H-18 to C-25 (δ~C~ 175.1), respectively.

The relative stereochemistry of **1** was elucidated by correlations in the NOESY experiment. Using the conventional method for analyzing the stereochemistry, the α*-* and β*-*configurations were assigned at H-5 and C-10-hydroxymethyl, respectively, to anchor the stereochemical analysis. In the NOESY spectrum of **1** ([Figure 3](#marinedrugs-18-00076-f003){ref-type="fig"}), H-9 correlated with H-5, but not with H~3~-21 and H~2~-22, suggesting that these two protons (H-5 and H-9) were situated on the same face and were α-oriented, and that the Me-21 and C-10-hydroxymethyl groups were β-oriented at C-8 and C-10, respectively. H-14 exhibited correlations with H-9 and H-18, but not with H~3~-21 and H~3~-23, demonstrating that H-14 and H-18 were α-oriented. Additionally, the proton signal of a methyl group at δ~H~ 0.96 (H~3~-23) displayed a correlation with H-12 (δ~H~ 4.77), which indicated the β-orientations of Me-23 and H-12. The NOESY spectrum showed a correlation between H~3~-26 and H-16, revealing the *E* geometry of the C-16/17 carbon--carbon double bond. It was found that the NMR data of **1** were similar to those of a known scalarane analogue, 12*α*-acetoxy-22-hydroxy-24-methyl-24-oxoscalar-16-en-25-al (**5**), from an Australian sponge, *Lendenfeldia* sp. \[[@B17-marinedrugs-18-00076]\], except that the aldehyde group in **5** was replaced by a carboxylic acid group in **1**. Based on the above findings, the structure of **1** was accordingly assigned, as shown in [Figure 1](#marinedrugs-18-00076-f001){ref-type="fig"}, and named lendenfeldarane A ([Supplementary Materials, Figures S1--S8](#app1-marinedrugs-18-00076){ref-type="app"}).

Compound **2** (lendenfeldarane B) was obtained as an amorphous powder and its molecular formula was determined as C~26~H~40~O~6~, based on a sodiated adduct ion peak \[M + Na\]^+^ at *m/z* 471.27171 in (+)-HRESIMS (calcd. for C~26~H~40~O~6~ + Na, 471.27142). The ^1^H NMR data of **2** ([Table 1](#marinedrugs-18-00076-t001){ref-type="table"}) showed five singlet methyls at δ~H~ 0.76, 0.87, 1.30, 1.34, and 2.40 and one oxymethine proton at δ~H~ 3.53 (1H, ddd, *J* = 10.8, 10.8, 4.8 Hz). The diastereotopic geminal protons at δ~H~ 3.93 (1H, dd, *J* = 11.4, 1.2 Hz) and 4.08 (1H, d, *J* = 11.4 Hz) were assumed to be an oxygenated methylene group. The ^13^C and DEPT data of **2** suggested the presence of 26 carbons that were similar to those of a known scalarane, felixin F (**6**) \[[@B18-marinedrugs-18-00076]\], including a carboxylic carbon at δ~C~ 172.4, two ketone carbons at δ~C~ 212.6 and 221.9, an oxymethine carbon at δ~C~ 72.7, and an oxymethylene carbon at δ~C~ 62.7. Analysis of these NMR data suggested that compounds **2** and **6** are closely related, with the only difference being that the β- aldehyde group at C-18 in **6** was replaced by a β-carboxylic acid group in **2**. Based on the analyses of the COSY, HMBC, and NOESY spectra, as well as the specific rotation data (**2**: \[α\]${}_{D}^{20}$ +49 (*c* 0.99, CHCl~3~), **6**: \[α\]${}_{D}^{20}$ +55 (*c* 0.04, CHCl~3~); ref \[[@B18-marinedrugs-18-00076]\] **6**: \[α\]${}_{D}^{25}$ +54 (*c* 0.4, CHCl~3~)), Compound **2** was finally assigned, as shown in [Figure 1](#marinedrugs-18-00076-f001){ref-type="fig"}, and named as lendenfeldarane B ([Supplementary Materials, Figures S9--S16](#app1-marinedrugs-18-00076){ref-type="app"}).

The molecular formula of lendenfeldarane C (**3**) was determined as C~26~H~40~O~4~ from an \[M + Na\]^+^ ion at m/z 439.28188 (calcd. for C~26~H~40~O~4~ + Na, 439.28174) and NMR data ([Table 2](#marinedrugs-18-00076-t002){ref-type="table"}), indicating seven degrees of unsaturation. The ^1^H NMR data of **3** showed four singlet methyls at δ~H~ 0.78, 0.86, 1.08, 1.13, one doublet methyl at δ~H~ 1.37 (J = 6.5 Hz), and two oxymethine protons at δ~H~ 4.60 (1H, br s) and 4.79 (1H, q, J = 6.5 Hz). The diastereotopic geminal protons at δ~H~ 3.92 (1H, d, J = 11.5 Hz) and 4.05 (1H, d, J = 11.5 Hz) were assumed to be an oxymethylene group. Analyses of the ^13^C NMR and DEPT spectrum of **3** revealed the existence of 26 carbon resonances, including five methyls, nine sp^3^ methylenes (including one oxymethylene), five sp^3^ methines (including two oxymethines), four sp^3^ quaternary carbons, and three sp^2^ quaternary carbons (including one ester carbonyl). Based on the ^13^C spectrum, **3** was found to possess an ester carbonyl (δ~C~ 172.6) and an unsaturated degree was indicated by the ^13^C chemical shifts at δ~C~ 133.5 (C-18) and 165.2 (C-17), suggesting the presence of a tetrasubstituted olefin. Thus, the above NMR data and the remaining five unsaturated degrees of **3** required a pentacyclic analogue.

The gross structure of **3** was constructed from its 2D NMR spectra. From the COSY spectrum ([Figure 2](#marinedrugs-18-00076-f002){ref-type="fig"}), five partial structure units between H~2~-1/H~2~-2/H~2~-3, H-5/H~2~-6/H~2~-7, H-9/H~2~-11/H-12, H-14/ H~2~-15/H~2~-16, and H-24/H~3~-26 were established. The HMBC spectrum connected these fractional structures by the key correlations between H-5/C-10; H~2~-15/C-17; H~3~-20/C-3, C-4, C-5, C-19; H~3~-21/ C-7, C-8, C-9, C-14; H~2~-22/C-1, C-9, C-10; and H~3~-23/C-12, C-13, C-14, C-18, indicating a scalarane skeleton. The COSY correlation between H~3~-26/H-24 and the HMBC from H-24 to C-17, C-18, and C-25 allowed the establishment of a 5-methyl-2(5H)-furanone. In the NOESY experiement of **3** ([Figure 3](#marinedrugs-18-00076-f003){ref-type="fig"}), H~3~-23 correlated with H~3~-21 and H-12, indicating the β-orientation of Me-23 and H-12, respectively. The orientation of Me-26 was determined to be β-oriented, based on the comparison of the NMR chemical shifts of Me-26 (δ~H~ 1.37, 3H, d, J = 6.5 Hz; δ~C~ 18.5) in **3** with those of previous reported scalarane analogues, phyllactones A (δ~H~ 1.51, 3H, d, J = 6.5 Hz; δ~C~ 19.6) and B (δ~H~ 1.38, 3H, d, J = 6.5 Hz; δ~C~ 18.5) ([Figure 4](#marinedrugs-18-00076-f004){ref-type="fig"}) \[[@B5-marinedrugs-18-00076]\]. Hence, the structure of **3** was determined to be a new sesterterpenoid and this metabolite was found to be the 12-epi-compound of a known 24- homoscalarane, 23-hydroxy-20-methylscalarolide \[[@B19-marinedrugs-18-00076],[@B20-marinedrugs-18-00076]\], and should be named lendenfeldarane C ([Supplementary Materials](#app1-marinedrugs-18-00076){ref-type="app"}, [Figures S17--S24](#app1-marinedrugs-18-00076){ref-type="app"}).

Compound **4** (lendenfeldarane D) has a molecular formula of C~30~H~44~O~6~, as established by (+)- HRESIMS at m/z 523.30301 (calcd. for C~30~H~44~O~6~ + Na, 523.30307). The ^1^H and ^13^C NMR data indicated that **4** possessed a structural skeleton similar to that of **3** ([Table 2](#marinedrugs-18-00076-t002){ref-type="table"}). Comparison of the ^1^H and ^13^C NMR spectra of **4** with those of **3** revealed that the C-12 oxymethine resonance at δ~C~ 69.9 observed in **3** was moved to δ~C~ 73.8 in **4**, and the C-22 oxymethene resonance at δ~C~ 63.0 observed in **3** was moved to δ~C~ 64.7 in **4**. Similarly, the ^1^H NMR spectrum of **4** displayed two additional acetate methyl signals at δ~H~ 1.97 and 2.07 (both 3H × s), relative to **3**. Therefore, the differences between compounds **3** and **4** are that the hydroxy groups at C-12 and C-22 in **3** were replaced by acetoxy groups in **4**. The gross structure of **4** is supported by the HMBC and COSY correlations ([Figure 2](#marinedrugs-18-00076-f002){ref-type="fig"}). The stereochemical configuration was identical to that of other scalarane sesterterpenes based on the NOESY cross- peaks at H-5/H-9, H-9/H-14, H~3~-20/H-22, H-22/H~3~-21, H~3~-21/H~3~-23, and H~3~-23/H-12 ([Figure 3](#marinedrugs-18-00076-f003){ref-type="fig"}). Thus, the structure of **4** was determined and named as lendenfeldarane D ([Supplementary Materials, Figures S25--S32](#app1-marinedrugs-18-00076){ref-type="app"}).

Based on the cytotoxicity that was demonstrated by the EtOAc extract of Lendenfeldia sp., all of the isolates **1**--**7** were assessed for their cytotoxicity toward the cancer cell lines MOLT-4, K-562, U-937, and SUP-T1 ([Table 3](#marinedrugs-18-00076-t003){ref-type="table"}). Compound **5** showed the most potent cytotoxicity toward MOLT-4 cells (IC~50~ = 0.31 μM). Since both compounds **5** and **7** were the major components, it was suggested that the cytotoxicity of the extract from Lendenfeldia sp. was attributed to these two scalaranes and the aldehyde groups in **5** and **7** played a significant role in their cytotoxicity.

3. Material and Methods {#sec3-marinedrugs-18-00076}
=======================

3.1. General Experimental Procedures {#sec3dot1-marinedrugs-18-00076}
------------------------------------

The optical rotation values were measured using a Jasco P-1010 digital polarimeter (Jasco, Tokyo, Japan). The IR spectra were obtained with a Thermo Scientific Nicolet iS5 FT-IR spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). The NMR spectra were recorded on a 600 or a 400 MHz Jeol ECZ NMR (Jeol, Tokyo, Japan) and a 500 MHz Varian Unity INOVA NMR spectrometer (Varian, Palo Alto, CA, USA), using the residual CHCl~3~ signals (δ~H~ 7.26 ppm) and CDCl~3~ (δ~C~ 77.0 ppm) as the internal standards for ^1^H and ^13^C NMR, respectively. The coupling constants (J) are presented in Hz. ESIMS and HRESIMS were recorded using a Bruker 7 Tesla solariX FTMS system (Bruker, Bremen, Germany). The column chromatography was carried out with silica gel (230--400 mesh; Merck, Darmstadt, Germany). The TLC was performed on plates that were precoated with Kieselgel 60 F~254~ (0.25 mm thick, Merck, Darmstadt, Germany), then sprayed with 10% H~2~SO~4~ solution, followed by heating to visualize the spots. The normal-phase HPLC (NP-HPLC) was performed using a system comprising a pump (L-7110; Hitachi, Tokyo, Japan), an injection port (Rheodyne, 7725; Rohnert Park, CA, USA), and a semi-preparative normal-phase column (YMC- Pack SIL, 250 × 20 mm, 5 μm; Sigma-Aldrich, St. Louis, MO, USA). The reverse-phase HPLC (RP- HPLC) was performed using a system comprising a pump (L-2130; Hitachi), a photodiode array detector (L-2455; Hitachi), an injection port (Rheodyne; 7725), and a reverse-phase column (Luna 5 μm, C18(2) 100Å AXIA Packed, 250 × 21.2 mm; Phenomenex, Torrance, CA, USA).

3.2. Animal Material {#sec3dot2-marinedrugs-18-00076}
--------------------

The specimens of the marine sponge *Lendenfeldia* sp. were collected by hand, using self-contained underwater breathing apparatus (SCUBA), while diving off the coast of Southern Taiwan on 5 September 2012, and stored in a freezer until extraction. The sponge material was identified by Dr. Yusheng M. Huang, Department of Marine Recreation, National Penghu University of Science and Technology, Taiwan, by comparison---as described in a previous publication \[[@B21-marinedrugs-18-00076]\]. A voucher specimen (NMMBA-TWSP-12006) was deposited in the National Museum of Marine Biology and Aquarium, Pingtung, Taiwan.

3.3. Extraction and Isolation {#sec3dot3-marinedrugs-18-00076}
-----------------------------

The sliced bodies of *Lendenfeldia* sp. (wet weight 1.21 kg) were extracted with EtOAc. The EtOAc layer (5.09 g) was separated on silica gel and eluted using a mixture of *n*-hexane and EtOAc (stepwise, 100:1--pure EtOAc) to yield 11 fractions A--K. Fraction F was separated by NP-HPLC, using a mixture of *n*-hexane and EtOAc (3:1, flow rate: 3.0 mL/min) to afford seven fractions F1--F7. Fraction F3 was separated by RP-HPLC using a mixture of MeOH and H~2~O (7:3, flow rate: 5 mL/min) to afford **4** (1.2 mg). Fraction G was chromatographed on silica gel and eluted using *n*-hexane/ acetone (8:1---pure acetone) to afford eight fractions G1--G8. Fraction G3 was separated by NP-HPLC using a mixture of *n*-hexane and acetone (2.5:1, flow rate: 3.0 mL/min) to afford 10 fractions G3A-- G3J, including Compound **7** (fraction G3C, 57.5 mg). Fraction G3D was separated by RP-HPLC using a mixture of MeOH and H~2~O (8:2, flow rate: 5 mL/min) to afford **3** (0.8 mg). Fraction H was separated on silica gel and eluted using a mixture of *n*-hexane and acetone (6:1--2:1) to obtain 14 fractions H1--H14. Fraction H5 was re-purified by NP-HPLC, using a mixture of *n*-hexane and acetone (5:1, flow rate: 3.0 mL/min) to afford **5** (49.2 mg) and **6** (2.0 mg), respectively. Fraction K was separated by NP-HPLC using a mixture of *n*-hexane and acetone (2:1, flow rate: 3.0 mL/min) to afford **1** (11.4 mg) and **2** (7.6 mg).

Lendenfeldarane A (**1**): amorphous powder; \[α\]${}_{D}^{20}$ +17 (*c* 0.99, CHCl~3~); IR (ATR) ν~max~ 3552--2420 (broad), 3467, 1716, 1667 cm^−1^; ^1^H (CDCl~3~, 400 MHz) and ^13^C (CDCl~3~, 100 MHz) NMR data, see [Table 1](#marinedrugs-18-00076-t001){ref-type="table"}; ESIMS: *m/z* 497 \[M + Na\]^+^; HRESIMS: *m/z* 497.28736 (calcd. for C~28~H~42~O~6~ + Na, 497.28712).

Lendenfeldarane B (**2**): amorphous powder; \[α\]${}_{D}^{20}$ +49 (*c* 0.99, CHCl~3~); IR (ATR) ν~max~ 3444--2309 (broad), 3399, 1740, 1730 cm^−1^; ^1^H (CDCl~3~, 600 MHz) and ^13^C (CDCl~3~, 150 MHz) NMR data, see [Table 1](#marinedrugs-18-00076-t001){ref-type="table"}; ESIMS: *m/z* 471 \[M + Na\]^+^; HRESIMS: *m/z* 471.27171 (calcd. for C~26~H~40~O~6~ + Na, 471.27142).

Lendenfeldarane C (**3**): amorphous powder; \[α\]${}_{D}^{20}$ +56 (*c* 0.04, CHCl~3~); IR (ATR) ν~max~ 3436, 1731 cm^−1^; ^1^H (CDCl~3~, 500 MHz) and ^13^C (CDCl~3~, 125 MHz) NMR data, see [Table 2](#marinedrugs-18-00076-t002){ref-type="table"}; ESIMS: *m/z* 439 \[M + Na\]^+^; HRESIMS: *m/z* 439.28188 (calcd. for C~26~H~40~O~4~ + Na, 439.28174).

Lendenfeldarane D (**4**): amorphous powder; \[α\]${}_{D}^{20}$ +38 (*c* 0.05, CHCl~3~); IR (ATR) ν~max~ 1738, 1672 cm^−1^; ^1^H (CDCl~3~, 600 MHz) and ^13^C (CDCl~3~, 150 MHz) NMR data, see [Table 2](#marinedrugs-18-00076-t002){ref-type="table"}; ESIMS: *m/z* 523 \[M + Na\]^+^; HRESIMS: *m/z* 523.30301 (calcd. for C~30~H~44~O~6~ + Na, 523.30307).

12α-Acetoxy-22-hydroxy-24-methyl-24-oxoscalar-16-en-25-al (**5**): amorphous powder; \[α\]${}_{D}^{20}$ +24 (*c* 2.46, CHCl~3~); IR (ATR) ν~max~ 1732, 1702, 1662 cm^−1^; ^1^H (CDCl~3~, 400 MHz) and ^13^C (CDCl~3~, 100 MHz) NMR data were found to be in complete agreement with previous report \[[@B17-marinedrugs-18-00076]\]; ESIMS: *m/z* 481 \[M + Na\]^+^.

Felixin F (**6**): amorphous powder; \[α\]${}_{D}^{20}$ +55 (*c* 0.04, CHCl~3~) (ref. \[[@B18-marinedrugs-18-00076]\] \[α\]${}_{D}^{25}$ +54 (*c* 0.4, CHCl~3~)); IR (ATR) ν~max~ 3430, 1701 cm^−1^; ^1^H (CDCl~3~, 400 MHz) and ^13^C (CDCl~3~, 100 MHz) NMR data were found to be in complete agreement with previous report \[[@B18-marinedrugs-18-00076]\]; ESIMS: *m/z* 455 \[M + Na\]^+^.

24-Methyl-12,24,25-trioxoscalar-16-en-22-oic acid (**7**): amorphous powder; \[α\]${}_{D}^{20}$ +68 (*c* 0.04, CHCl~3~) (ref. \[[@B17-marinedrugs-18-00076]\] \[α\]${}_{D}^{21}$ +33.5 (*c* 1, CHCl~3~)); IR (ATR) ν~max~ 3468--2388 (broad), 1732, 1702, 1662 cm^--1^; ^1^H (CDCl~3~, 400 MHz) and ^13^C (CDCl~3~, 100 MHz) NMR data were found to be in complete agreement with previous report \[[@B17-marinedrugs-18-00076]\]; ESIMS: *m/z* 451 \[M + Na\]^+^.

3.4. MTT Cell Proliferative Assay {#sec3dot4-marinedrugs-18-00076}
---------------------------------

The anti-proliferative properties of the metabolites against a limited panel of human tumor cell lines, including MOLT-4, K-562, U-937, and SUP-T1, were assayed. The cell lines were purchased from the American Type Culture Collection (ATCC). The cells were seeding at 2 × 10^4^ and were cultured in 96-well plates. The cytotoxic effect of the tested compounds was determined by the (3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-cell proliferation assay (Sigma- M2128; Sigma-Aldrich, St. Louis, MO, USA) after 72 h. A total of 50 μL of MTT solution was added to each well for 1 h and an ELISA reader (Anthoslabtec Instrument, Salzburg, Austria) was used (OD = OD~570~ − OD~620~) for the IC~50~ value, calculated with CalcuSyn software.

4. Conclusions {#sec4-marinedrugs-18-00076}
==============

The marine sponge belonging to the genus *Lendenfeldia* has proven to be a prolific producer of bioactive metabolites, especially sesterterpenoids with a scalarane skeleton. In the present study, seven 24-homoscalaranes were obtained from the *Lendenfeldia* sp. that was collected from the waters of Southern Taiwan, including four new 24-homoscalaranes, lendenfeldaranes A--D (**1**--**4**), along with three known analogues, 12α-acetoxy-22-hydroxy-24-methyl-24-oxo-scalar-16-en-25-al (**5**), felixin F (**6**), and 24-methyl-12,24,25-trioxoscalar-16-en-22-oic acid (**7**). The anti-cancer assessments indicated that **5**--**7** showed the most promising anti-proliferative activities against tumor cells. The structure-activity relationship (SAR) discussions also suggested the pivotal role of 18-aldehyde functionality in the activity against leukemia and lymphoma. Overall, these results can support the potential use of the marine sponge, genus *Lendenfeldia*, as a therapeutic agent in the treatment of cancer. We have therefore begun to culture this potentially useful sponge in tanks, using our highly developed aquaculture technology, for the extraction of natural products in order to establish a stable supply of bioactive materials, which will also protect the natural population and habitats from over-exploitation.
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The ^1^H and ^13^C NMR data for 24-homoscalaranes **1** and **2** (CDCl~3~).

  C/H      1                                    2                                                         
  -------- ------------------------------------ ------------- ------------------------------------------- -------------
  1        2.12 m; 0.48 ddd (12.8, 12.8, 3.2)   34.4, CH~2~   2.13 m; 0.80 m                              33.8, CH~2~
  2        1.50 m                               17.8, CH~2~   1.44 m; 1.65 m                              17.9, CH~2~
  3        1.19 m; 1.43 m                       41.6, CH~2~   1.18 m; 1.43 m                              41.4, CH~2~
  4                                             33.0, C                                                   33.0, C
  5        0.94 m                               56.8, CH      0.95 br d (12.6)                            56.8, CH
  6        1.43 m                               18.3, CH~2~   1.53 m                                      18.2, CH~2~
  7        1.03 m; 1.82 ddd (12.8, 3.2, 3.2)    42.2, CH~2~   0.96 m; 1.91 ddd (13.2, 3.6, 3.6)           42.1, CH~2~
  8                                             37.8, C                                                   38.7, C
  9        1.50 m                               49.3, CH      1.26 m                                      62.8, CH
  10                                            41.7, C                                                   42.8, C
  11       2.07 m                               24.9, CH~2~   2.62 dd (12.6, 1.8); 3.34 dd (14.4, 12.6)   39.0, CH~2~
  12       4.77 br s                            75.7, CH                                                  221.9, C
  13                                            38.9, C                                                   52.8, C
  14       1.31 m                               52.2, CH      1.21 m                                      58.0, CH
  15       2.27 m                               23.3, CH~2~   1.65 m; 1.94 ddd (12.6, 4.2, 1.8)           30.1, CH~2~
  16       6.90 br s                            139.7, CH     3.53 ddd (10.8, 10.8, 4.8)                  72.7, CH
  17                                            137.9, C      3.22 dd (12.0, 10.8)                        54.8, CH
  18       3.79 br s                            48.0, CH      3.18 d (12.0)                               51.3, CH
  19       0.75 s                               21.9, CH~3~   0.76 s                                      21.7, CH~3~
  20       0.86 s                               33.8, CH~3~   0.87 s                                      33.7, CH~3~
  21       1.16 s                               16.1, CH~3~   1.30 s                                      16.4, CH~3~
  22       3.85 d (11.6); 4.02 d (11.6)         62.9, CH~2~   3.93 dd (11.4, 1.2); 4.08 d (11.4)          62.7, CH~2~
  23       0.96 s                               15.5, CH~3~   1.34 s                                      15.3, CH~3~
  24                                            199.3, C                                                  212.6, C
  25                                            175.1, C                                                  172.4, C
  26       2.29 s                               25.3, CH~3~   2.40 s                                      33.4, CH
  OAc-12                                        170.4, C                                                  
           2.14 s                               21.5, CH~3~                                               

^a^ 400 MHz. ^b^ 100 MHz. ^c^ 600 MHz. ^d^ 150 MHz.
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###### 

The ^1^H and ^13^C NMR data for 24-homoscalaranes **3** and **4** (CDCl~3~).

  C/H      3                              4                                                  
  -------- ------------------------------ ------------- ------------------------------------ -------------
  1        2.16 m; 0.80 m                 34.0, CH~2~   2.01 m; 0.52 ddd (13.8, 13.8, 3.0)   34.7, CH~2~
  2        1.63 m                         18.4, CH~2~   1.63 m                               18.2, CH~2~
  3        1.18 m; 1.43 m                 41.7, CH~2~   1.15 ddd (9.0, 9.0, 4.2); 1.43 m     41.5, CH~2~
  4                                       33.0, C                                            33.0, C
  5        1.05 m                         56.8, CH      1.01 dd (13.8, 3.6)                  57.1, CH
  6        1.56 m; 1.91 m                 16.9, CH~2~   1.56 m; 1.93 m                       17.0, CH~2~
  7        1.10 m; 1.89 m                 42.0, CH~2~   1.11 ddd (12.0, 12.0, 4.2); 1.92 m   41.9, CH~2~
  8                                       37.6, C                                            37.5, C
  9        1.56 m                         52.3, CH      1.26 m                               53.2, CH
  10                                      41.8, C                                            40.2, C
  11       1.89 m; 2.18 m                 27.1, CH~2~   1.99 m; 2.20 m                       23.3, CH~2~
  12       4.60 br s                      69.9, CH      5.54 t (3.0)                         73.8, CH
  13                                      40.2, C                                            38.4, C
  14       1.60 m                         50.0, CH      1.55 m                               51.2, CH
  15       2.18 m; 2.35 m                 24.1, CH~2~   2.23 m; 2.39 m                       24.0, CH~2~
  16       1.46 m; 1.56 m                 18.0, CH~2~   1.60 m                               18.0, CH~2~
  17                                      165.2, C                                           163.6, C
  18                                      133.5, C                                           132.6, C
  19       0.78 s                         21.8, CH~3~   0.83 s                               21.9, CH~3~
  20       0.86 s                         33.9, CH~3~   0.89 s                               33.7, CH~3~
  21       1.08 s                         16.3, CH~3~   0.98 s                               16.4, CH~3~
  22       3.92 d (11.5); 4.05 d (11.5)   63.0, CH~2~   4.15 dd (12.0, 1.2); 4.58 d (12.0)   64.7, CH~2~
  23       1.13 s                         21.7, CH~3~   1.19 s                               21.3, CH~3~
  24       4.79 q (6.5)                   78.2, CH      4.78 q (6.0)                         77.7, CH
  25                                      172.6, C                                           171.1, C
  26       1.37 d (6.5)                   18.5, CH~3~   1.36 d (6.0)                         18.6, CH~3~
  OAc-12                                                                                     169.9, C
                                                        1.97 s                               21.2, CH~3~
  OAc-22                                                                                     170.9, C
                                                        2.07 s                               21.2, CH~3~

^a^ 500 MHz. ^b^ 125 MHz. ^c^ 600 MHz. ^d^ 150 MHz.
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###### 

The anti-proliferative effects of scalaranes **1**--**7**.

  Compound          Cell lines IC~50~ (μM)                  
  ----------------- ------------------------ ------- ------ -------
  1                 39.54                    NA      NA     33.02
  2                 34.93                    NA      NA     NA
  3                 6.31                     11.69   5.74   9.00
  4                 29.83                    NA      NA     NA
  5                 0.31                     3.04    2.35   5.90
  6                 5.67                     9.71    6.97   12.33
  7                 1.49                     1.04    5.88   7.49
  Doxorubicin ^a^   0.02                     0.13    0.04   0.09

^a^ Doxorubicin was used as a positive control; NA: not active at 20 μg/mL for 72 h.
